S&P 500   3,935.65 (-0.14%)
DOW   33,624.25 (+0.08%)
QQQ   279.96 (-0.61%)
AAPL   140.82 (-1.46%)
MSFT   244.10 (-0.42%)
META   113.34 (-0.68%)
GOOGL   95.02 (-2.02%)
AMZN   87.86 (-0.44%)
TSLA   173.28 (-3.64%)
NVDA   158.88 (-0.62%)
NIO   12.53 (-5.36%)
BABA   88.56 (-3.16%)
AMD   70.45 (+0.26%)
T   19.35 (+0.94%)
MU   53.38 (-0.56%)
CGC   3.29 (-8.86%)
F   13.27 (-0.08%)
GE   85.26 (-0.02%)
DIS   92.19 (-0.11%)
AMC   6.38 (-5.48%)
PYPL   73.80 (+2.17%)
PFE   50.44 (+1.47%)
NFLX   306.70 (+0.37%)
S&P 500   3,935.65 (-0.14%)
DOW   33,624.25 (+0.08%)
QQQ   279.96 (-0.61%)
AAPL   140.82 (-1.46%)
MSFT   244.10 (-0.42%)
META   113.34 (-0.68%)
GOOGL   95.02 (-2.02%)
AMZN   87.86 (-0.44%)
TSLA   173.28 (-3.64%)
NVDA   158.88 (-0.62%)
NIO   12.53 (-5.36%)
BABA   88.56 (-3.16%)
AMD   70.45 (+0.26%)
T   19.35 (+0.94%)
MU   53.38 (-0.56%)
CGC   3.29 (-8.86%)
F   13.27 (-0.08%)
GE   85.26 (-0.02%)
DIS   92.19 (-0.11%)
AMC   6.38 (-5.48%)
PYPL   73.80 (+2.17%)
PFE   50.44 (+1.47%)
NFLX   306.70 (+0.37%)
S&P 500   3,935.65 (-0.14%)
DOW   33,624.25 (+0.08%)
QQQ   279.96 (-0.61%)
AAPL   140.82 (-1.46%)
MSFT   244.10 (-0.42%)
META   113.34 (-0.68%)
GOOGL   95.02 (-2.02%)
AMZN   87.86 (-0.44%)
TSLA   173.28 (-3.64%)
NVDA   158.88 (-0.62%)
NIO   12.53 (-5.36%)
BABA   88.56 (-3.16%)
AMD   70.45 (+0.26%)
T   19.35 (+0.94%)
MU   53.38 (-0.56%)
CGC   3.29 (-8.86%)
F   13.27 (-0.08%)
GE   85.26 (-0.02%)
DIS   92.19 (-0.11%)
AMC   6.38 (-5.48%)
PYPL   73.80 (+2.17%)
PFE   50.44 (+1.47%)
NFLX   306.70 (+0.37%)
S&P 500   3,935.65 (-0.14%)
DOW   33,624.25 (+0.08%)
QQQ   279.96 (-0.61%)
AAPL   140.82 (-1.46%)
MSFT   244.10 (-0.42%)
META   113.34 (-0.68%)
GOOGL   95.02 (-2.02%)
AMZN   87.86 (-0.44%)
TSLA   173.28 (-3.64%)
NVDA   158.88 (-0.62%)
NIO   12.53 (-5.36%)
BABA   88.56 (-3.16%)
AMD   70.45 (+0.26%)
T   19.35 (+0.94%)
MU   53.38 (-0.56%)
CGC   3.29 (-8.86%)
F   13.27 (-0.08%)
GE   85.26 (-0.02%)
DIS   92.19 (-0.11%)
AMC   6.38 (-5.48%)
PYPL   73.80 (+2.17%)
PFE   50.44 (+1.47%)
NFLX   306.70 (+0.37%)
NYSE:DGX

Quest Diagnostics - DGX Stock Forecast, Price & News

$149.11
+0.14 (+0.09%)
(As of 12/7/2022 12:28 PM ET)
Add
Compare
Today's Range
$148.82
$149.92
50-Day Range
$122.69
$152.61
52-Week Range
$120.40
$174.16
Volume
9,917 shs
Average Volume
1.09 million shs
Market Capitalization
$16.98 billion
P/E Ratio
14.66
Dividend Yield
1.77%
Price Target
$148.50

Quest Diagnostics MarketRank™ Forecast

Analyst Rating
Hold
2.22 Rating Score
Upside/​Downside
0.3% Downside
$148.50 Price Target
Short Interest
Bearish
4.68% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.56
Upright™ Environmental Score
News Sentiment
0.41mentions of Quest Diagnostics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$9.17 M Sold Last Quarter
Proj. Earnings Growth
-14.21%
From $9.85 to $8.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

436th out of 1,023 stocks

Medical Laboratories Industry

12th out of 24 stocks

DGX stock logo

About Quest Diagnostics (NYSE:DGX) Stock

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Stock News Headlines

See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Company Calendar

Ex-Dividend for 10/19 Dividend
10/03/2022
Dividend Payable
10/19/2022
Last Earnings
10/20/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Ex-Dividend for 2/1 Dividend
1/17/2023
Dividend Payable
2/01/2023
Next Earnings (Estimated)
2/02/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
74834L10
Employees
49,000
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$148.50
High Stock Price Forecast
$170.00
Low Stock Price Forecast
$125.00
Forecasted Upside/Downside
-0.4%
Consensus Rating
Hold
Rating Score (0-4)
2.22
Research Coverage
9 Analysts

Profitability

Net Income
$2.00 billion
Pretax Margin
15.81%

Debt

Sales & Book Value

Annual Sales
$10.79 billion
Cash Flow
$18.25 per share
Book Value
$52.85 per share

Miscellaneous

Free Float
111,951,000
Market Cap
$16.98 billion
Optionable
Optionable
Beta
1.02

Social Links


Key Executives

  • Mr. Stephen H. RusckowskiMr. Stephen H. Rusckowski (Age 65)
    Exec. Chairman
    Comp: $4.3M
  • Mr. James E. Davis (Age 59)
    CEO, Pres & Director
    Comp: $1.51M
  • Ms. Catherine T. DohertyMs. Catherine T. Doherty (Age 59)
    Sr. VP of Regional Bus.es
    Comp: $1.24M
  • Mr. Sam A. Samad (Age 52)
    Exec. VP & CFO
  • Mr. Michael J. Deppe (Age 55)
    VP, Corp. Controller & Chief Accounting Officer
  • Ms. Gabrielle Wolfson
    Sr. VP and Chief Information & Digital Officer
  • Mr. Shawn C. Bevec
    VP of Investor Relations
  • Mr. Michael E. PrevoznikMr. Michael E. Prevoznik (Age 60)
    Sr. VP & Gen. Counsel
  • Ms. Kristin Lee Wallace Esq.
    Sr. VP of Compliance
  • Mr. Gary D. Samuels
    Sr. VP & Chief Communications Officer













DGX Stock - Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings
or view top-rated stocks.

What is Quest Diagnostics' stock price forecast for 2023?

9 analysts have issued 12-month price objectives for Quest Diagnostics' shares. Their DGX share price forecasts range from $125.00 to $170.00. On average, they expect the company's share price to reach $148.50 in the next twelve months. This suggests that the stock has a possible downside of 0.7%.
View analysts price targets for DGX
or view top-rated stocks among Wall Street analysts.

How have DGX shares performed in 2022?

Quest Diagnostics' stock was trading at $173.01 on January 1st, 2022. Since then, DGX shares have decreased by 13.6% and is now trading at $149.55.
View the best growth stocks for 2022 here
.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 5,290,000 shares, an increase of 5.6% from the October 31st total of 5,010,000 shares. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is currently 5.1 days. Approximately 4.7% of the company's shares are sold short.
View Quest Diagnostics' Short Interest
.

When is Quest Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our DGX earnings forecast
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) issued its quarterly earnings results on Thursday, October, 20th. The medical research company reported $2.36 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.17. The medical research company earned $2.49 billion during the quarter, compared to analysts' expectations of $2.34 billion. Quest Diagnostics had a trailing twelve-month return on equity of 21.36% and a net margin of 12.00%. The firm's revenue was down 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.96 EPS.
Read the conference call transcript
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Monday, November 14th. Investors of record on Wednesday, January 18th will be paid a dividend of $0.66 per share on Wednesday, February 1st. This represents a $2.64 annualized dividend and a dividend yield of 1.77%. The ex-dividend date of this dividend is Tuesday, January 17th.
Read our dividend analysis for DGX
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.64 per share and currently has a dividend yield of 1.77%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 25.96%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 31.24% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its board has authorized a share repurchase program on Thursday, February 4th 2021, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 6.1% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share (EPS) guidance of $9.75-$9.95 for the period, compared to the consensus earnings per share estimate of $8.44. The company issued revenue guidance of $9.72 billion-$9.86 billion, compared to the consensus revenue estimate of $8.51 billion.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.43%), BlackRock Inc. (11.15%), State Street Corp (5.25%), Victory Capital Management Inc. (2.83%), Dimensional Fund Advisors LP (1.87%) and Davis Selected Advisers (1.64%). Insiders that own company stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski and Timothy M Ring.
View institutional ownership trends
.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $149.55.

How much money does Quest Diagnostics make?

Quest Diagnostics (NYSE:DGX) has a market capitalization of $17.03 billion and generates $10.79 billion in revenue each year. The medical research company earns $2.00 billion in net income (profit) each year or $10.17 on an earnings per share basis.

How many employees does Quest Diagnostics have?

The company employs 49,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?
The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More
How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The official website for the company is www.questdiagnostics.com. The medical research company can be reached via phone at (973) 520-2700, via email at investor@questdiagnostics.com, or via fax at 201-462-4169.

This page (NYSE:DGX) was last updated on 12/7/2022 by MarketBeat.com Staff